Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

The relationship between early reversibility test and maximal inspiratory pressure in patients with airway obstruction

Authors Ozkaya S, Dirican A, Kaya SO, Karanfil RC, Bayrak MG, Bostancı O, Ece F

Received 2 December 2013

Accepted for publication 10 March 2014

Published 5 May 2014 Volume 2014:9(1) Pages 453—456

DOI https://doi.org/10.2147/COPD.S58584

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Sevket Ozkaya,1 Adem Dirican,2 Sule Ozbay Kaya,3 Rabia C Karanfil,3 Merve G Bayrak,4 Ozgür Bostancı,5 Ferah Ece1

1Department of Pulmonary Medicine, Faculty of Medicine, Bahcesehir University, Istanbul, 2Department of Pulmonary Medicine, 3Department of Physical Therapy and Rehabilitation Clinic, Samsun Medicalpark Hospital, 4Department of Pulmonary Medicine, Samsun Chest Diseases and Thoracic Surgery Hospital, 5Academy of Sports, Ondokuzmayis University, Samsun, Turkey

Abstract: Maximal inspiratory pressure (MIP) is a marker for assessing the degree of respiratory muscle dysfunction. Muscle dysfunction represents a pathophysiological feature of chronic obstructive pulmonary disease. We aimed to determinate the MIP value in patients with airway obstruction, to evaluate the change in MIP with bronchodilator drug, and to show the relationship between the changes in MIP and disease characteristics. We evaluated 21 patients with airway obstruction at the Department of Pulmonary Medicine, Samsun Medicalpark Hospital, Samsun, Turkey. We performed pulmonary function tests, measurement of MIP values, and reversibility tests with salbutamol. The baseline spirometry results were: mean forced vital capacity (FVC), 3,017±1,020 mL and 75.8%±20.8%; mean forced expiratory volume in 1 second (FEV1), 1,892±701 mL and 59.2%±18.2%; FEV1/FVC, 62.9%±5.5%; peak expiratory flow, 53%±19%. The pre-bronchodilator MIP value was 62.1±36.9 cmH2O. The reversibility test was found to be positive in 61.9% of patients with salbutamol. The absolute change and percentage of change in FEV1 were 318±223 mL and 19.8%±16.7%, respectively. The MIP value was increased by 5.5 cmH2O (8.8%) and was 67.7±30.3 cmH2O after bronchodilation. There was no significant relationship between age, FEV1, reversibility, and change in MIP with bronchodilator. However, the increase in MIP with bronchodilator drug was higher in patients with low body mass index (<25 kg/m2). We noted a 13.1% increase in FVC, a 19.8% increase in FEV1, a 20.2% increase in peak expiratory flow, and an 8.8% increase in MIP with salbutamol. In conclusion; MIP increases with bronchodilator therapy, regardless of changes in lung function, in patients with airway obstruction. The reversibilty test can be used to evaluate change in MIP with salbutamol.

Keywords: asthma, COPD, maximal inspiratory pressure, MIP, reversibility test, salbutamol


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Factors affecting patients’ comfort during fiberoptic bronchoscopy and endobronchial ultrasound

Yıldırım F, Özkaya Ş, Yurdakul AS

Journal of Pain Research 2017, 10:775-781

Published Date: 29 March 2017

The objective evaluation of obstructive pulmonary diseases with spirometry

Ozkaya S, Dirican A, Tuna T

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2009-2015

Published Date: 25 August 2016

The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases

Bayiz H, Ozkaya S, Dirican A, Ece F

Drug Design, Development and Therapy 2015, 9:5287-5290

Published Date: 21 September 2015

Thrombolytic treatment (alteplase; rt-PA) in acute massive pulmonary embolism and cardiopulmonary arrest

Dirican A, Ozkaya S, Atas AE, Ulu EK, Kitapci I, Ece F

Drug Design, Development and Therapy 2014, 8:759-763

Published Date: 12 June 2014

Long-term results of external valvuloplasty in adult patients with isolated great saphenous vein insufficiency

Sarac A, Jahollari A, Talay S, Ozkaya S, Ozal E

Clinical Interventions in Aging 2014, 9:575-579

Published Date: 5 April 2014

Diagnostic efficacy of computed tomography-guided transthoracic needle aspiration and biopsy in patients with pulmonary disease

Tuna T, Ozkaya S, Dirican A, Findik S, Atici AG, Erkan L

OncoTargets and Therapy 2013, 6:1553-1557

Published Date: 5 November 2013

The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis

Tasci C, Ozkaya S, Ozkara B, Tozkoparan E, Ozkan M, Karadurmus N, Serdar M, Balkan A, Bilgic H

OncoTargets and Therapy 2012, 5:385-390

Published Date: 22 November 2012

The costs of hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease

Sevket Ozkaya, Serhat Findik, Atilla Guven Atici

ClinicoEconomics and Outcomes Research 2011, 3:15-18

Published Date: 17 January 2011

Readers of this article also read:

An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line

Yu XZ, Di Y, Xie C, Song YL, He H, Li HC, Pu XM, Lu WY, Fu DL, Jin C

International Journal of Nanomedicine 2015, 10:6825-6834

Published Date: 30 October 2015

Synthesis and characterization of multifunctional hybrid-polymeric nanoparticles for drug delivery and multimodal imaging of cancer

Tng DJH, Song P, Lin G, Soehartono AM, Yang G, Yang C, Yin F, Tan CH, Yong KT

International Journal of Nanomedicine 2015, 10:5771-5786

Published Date: 15 September 2015

Molecular targets in arthritis and recent trends in nanotherapy

Roy K, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2015, 10:5407-5420

Published Date: 26 August 2015

Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system

Guo L, Zhang H, Wang F, Liu P, Wang Y, Xia G, Liu R, Li X, Yin H, Jiang H, Chen B

International Journal of Nanomedicine 2015, 10:4535-4547

Published Date: 16 July 2015

Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy

Arora S, Swaminathan SK, Kirtane A, Srivastava SK, Bhardwaj A, Singh S, Panyam J, Singh AP

International Journal of Nanomedicine 2014, 9:2933-2942

Published Date: 18 June 2014

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010